Evofem Biosciences, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net income was USD 66.01 million compared to USD 89.51 million a year ago. Basic earnings per share from continuing operations was USD 15.34 compared to USD 135.72 a year ago. Diluted earnings per share from continuing operations was USD 0.1 compared to diluted loss per share from continuing operations of USD 4.39 a year ago.
For the nine months, net income was USD 55.09 million compared to net loss of USD 68.36 million a year ago. Basic earnings per share from continuing operations was USD 21.42 compared to basic loss per share from continuing operations of USD 206.38 a year ago. Diluted earnings per share from continuing operations was USD 0.09 compared to diluted loss per share from continuing operations of USD 206.38 a year ago.